Le Lézard
Classified in: Health
Subjects: SVY, TRI

Specialty Enzymes & Probiotics Publishes New Clinical Study on Revolutionary Sports Nutrition Ingredient DigeSEB Sporttm


CHINO, Calif., April 17, 2024 /PRNewswire/ -- A new clinical study shows DigeSEB Sporttm, a potent sports nutrition ingredient offered by Specialty Enzymes & Probiotics, promotes protein digestion and nutrient bioavailability, a healthy gut microbiome, and the production of postbiotics, such as GABA and ?-alanine.

The objective of the newly published study, titled "Metabolomics and Gut Metagenomics Profile of the Healthy Adults on Consumption of Whey Protein Supplemented with Enzymes-Probiotics Blend," was to evaluate how supplementing whey protein with DigeSEB Sporttm, a unique blend of proteolytic enzymes, probiotics and a prebiotic, impacts amino acid absorption and the gut microbiome.

Results showed the addition of DigeSEB Sporttm, formerly Pepzyme Protm, to whey protein led to an increased rate of amino acid absorption and the augmentation of total absorption of essential and branched-chain amino acids within 30 minutes of protein consumption.

In addition, noteworthy changes were observed in the gut microbiota profile, with a significant increase in the abundance of several species of Bacteroides. Bacteroides are known to have prototypic activity and be beneficial to the gut microbiome.

An unexpected study result found that supplementation with DigeSEB Sporttm increased the production of postbiotics GABA, L-citrulline, ?-alanine and L-ornithine. These postbiotics have been shown to offer a wide range of benefits - everything from supporting a healthy response to stress, anxiety and depression, to promoting skin health, physical endurance, healthy aging, inflammation and cardiac health.

"The findings of this research hold significant implications for the sports nutrition and supplemental protein industries," said Vic Rathi, CEO & Founder of Specialty Enzymes & Probiotics. "Improving digestion and nutrient absorption from supplemental protein, thus maximizing consumer gain, meets a vital need in today's market."

About Specialty Enzymes and Probiotics:
Specialty Enzymes & Probiotics is a research-driven manufacturer with more than 45 years of fermentation experience. The company's innovative and scientifically formulated synbiotic, probiotic and enzyme solutions are shown in studies to promote joint, muscle, cardiovascular, immune, gut and digestive health.

Products are manufactured in the company's state-of-the-art, NSF GMP-certified manufacturing facilities, which boast a long list of elite accreditations, including The Non-GMO Project, OK Kosher and ISA Halal. The company's on-site ISO-17025-certified laboratory offers full-service testing. Specialty Enzymes & Probiotics is a proud member of the International Probiotic Association (IPA) and Council for Responsible Nutrition (CRN).

SOURCE Specialty Enzymes & Probiotics


These press releases may also interest you

at 20:00
Zimmerman Reed announced today that the United States and the State of California reached a $7 million settlement with ReNew Health Group LLC, ReNew Health Consulting Services LLC, and its owner-CEO and its COO to resolve False Claims Act allegations...

at 19:15
In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio)...

at 18:50
Ontario's forest firefighters will soon have the same presumptive WSIB coverage that urban firefighters do. Like urban firefighters, forest firefighters are at a higher risk of cancer, heart disease and heart injuries, and post-traumatic stress...

at 18:49
A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy...

at 18:45
Pfizer Inc. and Genmab A/S today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with...

at 18:45
Genmab A/S and Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or...



News published on and distributed by: